Literature DB >> 19288121

Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis.

Jane Marian Anderson1, Rickie Patani, Richard Reynolds, Richard Nicholas, Alastair Compston, Maria Grazia Spillantini, Siddharthan Chandran.   

Abstract

Although progression in multiple sclerosis is pathologically dominated by neurodegeneration, the underlying mechanism is unknown. Abnormal hyperphosphorylation of tau is implicated in the aetiopathogenesis of some common neurodegenerative disorders. We recently demonstrated the association of insoluble tau with established secondary progressive MS, raising the hypothesis that its accumulation is relevant to disease progression. In order to begin to determine the temporal emergence of abnormal tau with disease progression in MS, we examined tau phosphorylation in cerebral tissue from a rare case of early aggressive MS. We report tau hyperphosphorylation occurring in multiple cell types, with biochemical analysis confirming restriction to the soluble fraction. The absence of sarcosyl-insoluble tau fraction in early disease and its presence in secondary progression raises the possibility that insoluble tau accumulates with disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288121     DOI: 10.1007/s00401-009-0515-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  15 in total

1.  Inducible Expression of a Truncated Form of Tau in Oligodendrocytes Elicits Gait Abnormalities and a Decrease in Myelin: Implications for Selective CNS Degenerative Diseases.

Authors:  Patrizia LoPresti
Journal:  Neurochem Res       Date:  2015-09-22       Impact factor: 3.996

2.  Mice devoid of Tau have increased susceptibility to neuronal damage in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.

Authors:  Jason G Weinger; Peter Davies; Christopher M Acker; Celia F Brosnan; Vladislav Tsiperson; Ashrei Bayewitz; Bridget Shafit-Zagardo
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

3.  Sex-specific Tau methylation patterns and synaptic transcriptional alterations are associated with neural vulnerability during chronic neuroinflammation.

Authors:  Alessandro Didonna; Ester Cantó; Hengameh Shams; Noriko Isobe; Chao Zhao; Stacy J Caillier; Carlo Condello; Hana Yamate-Morgan; Seema K Tiwari-Woodruff; Mohammad R K Mofrad; Stephen L Hauser; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2019-04-19       Impact factor: 7.094

Review 4.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

5.  Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes.

Authors:  Milena De Riz; Daniela Galimberti; Chiara Fenoglio; Laura M Piccio; Diego Scalabrini; Eliana Venturelli; Anna Pietroboni; Mirko Piola; Robert T Naismith; Becky J Parks; Giorgio Fumagalli; Nereo Bresolin; Anne H Cross; Elio Scarpini
Journal:  Neurosci Lett       Date:  2009-12-04       Impact factor: 3.046

6.  Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2010-06-12       Impact factor: 6.543

7.  Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies.

Authors:  Dirk Fitzner; Mikael Simons
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

8.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

Review 9.  Tau at the interface between neurodegeneration and neuroinflammation.

Authors:  Alessandro Didonna
Journal:  Genes Immun       Date:  2020-10-03       Impact factor: 2.676

Review 10.  Experimental and therapeutic opportunities for stem cells in multiple sclerosis.

Authors:  Rickie Patani; Siddharthan Chandran
Journal:  Int J Mol Sci       Date:  2012-11-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.